ENO1 and pancreatic neoplasm: GLS inhibition significantly decreased CFPAC-1, but not MDA-MB-231 or NCI-H441 cell survival, suggesting that pancreatic cancer cells are considerably more sensitive to GLS inhibition when ENO1 function is impaired (Supplementary Figure S10A).